The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.
Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US Food and Drug Administration (FDA). The ...
As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...
US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...
Korea Joongang Daily on MSN21h
Celltrion's Actemra biosimilar gets FDA approvalCelltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.
On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...
The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.
Yonhap News English on MSN9d
Celltrion’s Autoimmune Disease Treatment Hits 5 Major European CountriesSEOUL, Jan. 23 (Korea Bizwire) — Celltrion Inc.’s autoimmune disease treatment, SteQeyma, has been launched in five major ...
The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback